US Stock Market Move | CEO stated that they will continue to provide the Wegovy combination drug, resulting in Hims & Hers Health (HIMS.US) increasing by over 6%.

On Thursday, the stock price of Hims & Hers Health (HIMS.US) rose, and as of the time of writing, the stock rose by more than 6%, reaching $44.17. In terms of news, Novo Nordisk A/S Sponsored ADR Class B (NVO.US) recently ended its partnership with Hims & Hers Health to distribute the weight loss therapy Wegovy (semaglutide). However, Hims & Hers CEO Andrew Dudum stated that their telemedicine platform will still offer affordable Wegovy compounded medication.